CoChat

Quality of Life in Advanced Prostate Cancer: Results of a Randomized Therapeutic Trial

Open access
Moinpour, C. M., Lovato, L. C., Yee, M., Blumenstein, B. A., Savage, M. J., Troxel, A., Eisenberger, M., Veith, R. W., Higgins, B., Skeel, R., Crawford, E. D., Meyskens, F. L. · 1998 · JNCI Journal of the National Cancer Institute
Cited by 148

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

BACKGROUND: For patients with metastatic prostate cancer, treatment is primarily palliative, relying mainly on the suppression of systemic androgen hormone levels. To help document the achievement of palliation and to characterize positive and negative effects of treatment, we evaluated quality-of-life (QOL) parameters in patients with metastatic prostate cancer who were randomly assigned to two methods of androgen deprivation. METHODS: Patients (n = 739) with stage M1 (bone or soft tissue metastasis) prostate cancer were enrolled in a QOL protocol that was a companion to Southwest Oncology Group INT-0105, a randomized double-blind trial comparing treatment with bilateral orchiectomy (surgical castration) plus either flutamide or placebo. Patients completed a comprehensive battery of QOL questionnaires at random assignment to treatment and at 1, 3, and 6 months later. Data were collected on three treatment-specific symptoms (diarrhea, gas pain, and body image), on physical functioning, and on emotional functioning. All P values are two-sided. RESULTS: Questionnaire return rates for this study never dropped below 80%; only 2% of the patients did not submit baseline QOL assessments. Cross-sectional analyses (corrected for multiple testing) identified statistically significant differences that favored orchiectomy plus placebo for two of the five primary QOL parameters as follows: patients receiving flutamide reported more diarrhea at 3 months (P = .001) and worse emotional functioning at 3 and 6 months (both P<.003). Longitudinal analyses replicated these findings. Other analyzed QOL parameters favored the group receiving placebo but were not statistically significant after adjustment for multiple testing. CONCLUSIONS: We found a consistent pattern of better QOL outcomes at each follow-up assessment during the first 6 months of treatment for orchiectomized patients with metastatic prostate cancer who received placebo versus flutamide. Improvement over time was evident in both treatment groups but more so for patients receiving placebo.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/90.20.1537

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 148

Metadata

Authors
Moinpour, C. M., Lovato, L. C., Yee, M., Blumenstein, B. A., Savage, M. J., Troxel, A., Eisenberger, M., Veith, R. W., Higgins, B., Skeel, R., Crawford, E. D., & Meyskens, F. L.
Venue
JNCI Journal of the National Cancer Institute
Published
1998-10-21
Volume
90
Issue
20
Pages
1537-1544
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W2115744963
Cited by
148
References
7
FWCI
11.57
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Quality of Life in Advanced Prostate Cancer: Results of a Randomized Therapeutic Trial. https://app.cochat.ai/papers/10.1093/jnci/90.20.1537
The paper
Moinpour, C. M., Lovato, L. C., Yee, M., Blumenstein, B. A., Savage, M. J., Troxel, A., Eisenberger, M., Veith, R. W., Higgins, B., Skeel, R., Crawford, E. D., & Meyskens, F. L. (1998). Quality of Life in Advanced Prostate Cancer: Results of a Randomized Therapeutic Trial. JNCI Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/90.20.1537

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.